Lista de obras -

A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer

artículo científico publicado en 2006

A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors

artículo científico publicado en 2008

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

scientific article published on 14 February 2019

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

scientific article published on 29 October 2019

Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?

scientific article published on 05 February 2019

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

artículo científico publicado en 2020

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial ⬇️

scholarly article

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) ⬇️

scholarly article

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

artículo científico publicado en 2016

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma ⬇️

artículo científico publicado en 2011

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

artículo científico publicado en 2019

Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia

artículo científico publicado en 2018

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

scientific article published on 24 July 2020

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

artículo científico publicado en 2016

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2020

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia

artículo científico publicado en 2020

Bronchioloalveolar carcinoma: sonographic pattern of 'pneumonia'

artículo científico publicado en 2002

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

artículo científico publicado en 2013

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

artículo científico

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies

artículo científico publicado en 2015

Color Doppler sonographic mapping of pulmonary lesions: evidence of dual arterial supply by spectral analysis

artículo científico publicado en 2003

Color Doppler sonographic signs of respiration-dependent hepatofugal portal flow

artículo científico publicado en 2004

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2020

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

artículo científico publicado en 2013

Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL

scientific article published on 03 December 2019

Fatal bleeding complications caused by Evans syndrome (autoimmune thrombocytopenia and hemolytic anemia) and type II autoimmune hepatitis in a 56-year-old patient

artículo científico publicado en 2002

Focal splenic lesions in myeloproliferative disease: association with fatal outcome

artículo científico publicado en 2003

Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions

artículo científico publicado en 2016

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

artículo científico

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

artículo científico publicado en 2009

Immunotherapy using bispecific T cell engager (BiTE®) antibodies: preclinical and clinical experience in acute leukemia.

artículo científico publicado en 2014

Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells

artículo científico publicado en 2005

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) ⬇️

scholarly article

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

artículo científico publicado en 2017

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

artículo científico publicado en 2015

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

artículo científico publicado en 2020

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

scientific article published on 01 December 2019

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

artículo científico publicado en 2019

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

artículo científico publicado en 2007

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs) ⬇️

artículo científico publicado en 2016

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

artículo científico publicado en 2014

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2016

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy

artículo científico publicado en 2010

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

artículo científico publicado en 2014

Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients

scientific article published on 01 January 2004

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

artículo científico publicado en 2014

Significance of heparin-binding growth factor expression on cells of solid pediatric tumors

artículo científico publicado en 2003

Spontaneous nontraumatic intrasplenic pseudoaneurysm: causes, sonographic diagnosis, and prognosis

artículo científico publicado en 2003

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

scholarly article by Lia Gore et al published 22 August 2018 in Blood Cancer Journal

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

artículo científico publicado en 2011

The small spleen: sonographic patterns of functional hyposplenia or asplenia

artículo científico publicado en 2003

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

artículo científico publicado en 2008

[Antibodies in hematology by the example of acute lymphatic leukemia]

scientific article published on 01 October 2019

Lista de obras de

A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer

A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

Aneuploidy in childhood B cell acute lymphoblastic leukaemia - also a relevant prognostic factor in relapsed disease?

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL: Updated Results of An Ongoing Phase II Trial ⬇️

Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate and Prolongs Overall Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) ⬇️

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma ⬇️

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia

Bronchioloalveolar carcinoma: sonographic pattern of 'pneumonia'

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies

Color Doppler sonographic mapping of pulmonary lesions: evidence of dual arterial supply by spectral analysis

Color Doppler sonographic signs of respiration-dependent hepatofugal portal flow

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL

Fatal bleeding complications caused by Evans syndrome (autoimmune thrombocytopenia and hemolytic anemia) and type II autoimmune hepatitis in a 56-year-old patient

Focal splenic lesions in myeloproliferative disease: association with fatal outcome

Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

Immunotherapy using bispecific T cell engager (BiTE®) antibodies: preclinical and clinical experience in acute leukemia.

Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL) ⬇️

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs) ⬇️

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Significance of heparin-binding growth factor expression on cells of solid pediatric tumors

Spontaneous nontraumatic intrasplenic pseudoaneurysm: causes, sonographic diagnosis, and prognosis

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

The small spleen: sonographic patterns of functional hyposplenia or asplenia

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

[Antibodies in hematology by the example of acute lymphatic leukemia]